SYT-SSX fusion neoantigen-MHC complex

The SYT-SSX fusion neoantigen-MHC complex is a tumor-specific molecular complex found in synovial sarcoma, resulting from a chromosomal translocation t(X;18)(p11.2;q11.2) that fuses the SYT (also known as SS18) gene on chromosome 18 with an SSX gene (most commonly SSX1 or SSX2) on the X chromosome. This fusion encodes a unique chimeric protein, which, when processed by the proteasome, generates peptides (neoantigens) not present in normal tissues. These peptides are presented by MHC class I molecules on tumor cell surfaces, where they can be recognized by cytotoxic T lymphocytes, making them highly attractive targets for immunotherapeutic strategies in synovial sarcoma. The SYT-SSX protein contains both transcriptional activation and repression domains, altering gene regulation and driving sarcomagenesis. Variants (SYT-SSX1, SYT-SSX2, and rarely SYT-SSX4) exist, and the fusion type can impact clinical prognosis. Therapies in development or clinical study include T cell receptor (TCR)-engineered T cells and peptide vaccines targeting SYT-SSX peptide-MHC complexes. These complexes are not receptors or enzymes but are critical immune targets arising from the unique biology of synovial sarcoma.

Other names

SYT-SSX-derived neoantigen-MHC complexSS18-SSX fusion neoantigen-MHC complexSynovial sarcoma fusion neoantigen-MHC complex

Recognition by cytotoxic T lymphocytes (CTLs); Immune-mediated cell killing (therapeutics leverage CTL recognition of tumor cells presenting SYT-SSX–derived peptides on MHC)